search

Nanobiotix (NBTX)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Nanobiotix shares rise 3% and rank among the top performers of the SBF 120
Nov 5, 2026

Nanobiotix shares rise 3% and rank among the top performers of the SBF 120

Nanobiotix, an oncology nanomedicine biotech, saw its shares rise by 2.98% to €27.68, making it one of the top performers in the SBF 120 index, despite a weekly decline. The stock's rebound moved it above several short- and medium-term technical benchmarks, reflecting significant recent price volatility. The company reported a cash position of €110.9 million in September, sufficient to fund operations through 2029, and continues development of its radioenhancer NBTXR3 in partnership with Johnson & Johnson.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish